Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab in Acute Pyoderma Gangrenosum
NCT01882504Phase 2Completed
- Sponsor
- XOMA
- Start
- May 2013
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gevokizumab in pyoderma gangrenosum (PG), sponsored by XOMA. Primary endpoint: Improvement in the Investigator's Assessment of the pyoderma gangrenosum target ulcer at Day 84. Started May 2013; status: completed.
02
Drugs
gevokizumab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT01882504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01882504.